Following reported phase 1b results with drug candidate ACD440, we seized the opportunity to interview CEO Martin Jönsson and CSO Johan Sandin at Alzecure Pharma. In this interview, Martin and Johan elaborate on why they are enthusiastic about the results and the path forward in peripheral neuropathic pain.

info@redeye.se (Redeye.se)

Redeye AB - Redeye.se